checkAd

     165  0 Kommentare INTERIM REPORT FOR Q2 2022/23 AND THE HALF-YEAR - Seite 2


    PRODUCT AND PIPELINE UPDATES
    • On 23 March 2023, Ambu re-launched its unique one-lung ventilation solution, the Ambu VivaSightTM 2 DLT (double lumen tube). The solution re-enters the market with improved performance.
    • On 28 March 2023, Ambu obtained European regulatory clearance (CE mark) of two new smaller-sized fifth-generation bronchoscopes. The company hereby has a complete fifth-generation bronchoscope portfolio for a wide array of patient needs in the bronchoscopy suite.


    OTHER HIGHLIGHTS FROM Q2

    • Ambu presented updated market potential assumptions:
      • Number of procedures Ambu covers today: ~1.7m procedures
      • Number of procedures with marketed solutions and near-term pipeline: ~23m procedures
      • Current value of the total single-use endoscopy market: DKK ~5bn
      • Expected value of the total single-use endoscopy market in five years: DKK 15-20bn
    • From 23 March to 24 March 2023, Ambu strengthened its share capital base by selling 11,577,957 new B-shares and 250,000 existing treasury B-shares, corresponding to 5.3% of its B-share capital and approximately DKK 1.1bn.
    • In April 2023, Ambu donated 110,000+ products (including resuscitators and face masks) to Turkey to support in the rebuilding of hospitals after the devastating earthquakes in February 2023.
    • On 1 May 2023, Henrik Birk took on the role of Chief Operations Officer at Ambu. As an integral part of Ambu’s Executive Leadership Team, Henrik will drive execution and strategic direction across areas such as Manufacturing, Supply Chain, QA/RA and Procurement.


    LONG-TERM FINANCIAL TARGETS

    • Ambu specified its long-term financial targets at its Capital Markets Day on 21 March:
      • 5-year organic revenue CAGR (2022/23-2027/28): >10%
        • Endoscopy Solutions revenue growth: 15-20%
        • Anaesthesia and Patient Monitoring revenue growth (combined): 2-4%
      • EBIT margin before special items:
        • 2-year target: >10%
        • 5-year target: ~20% (2027/28)
      • Financial leverage: Less than 2.5x
    Seite 2 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    INTERIM REPORT FOR Q2 2022/23 AND THE HALF-YEAR - Seite 2 Ambu posts 4% organic revenue growth for the second quarter of 2022/23, in line with expectations. The quarter was driven by continued strong growth in urology and ENT, offset by pulmonology and Anaesthesia. Financial guidance is maintained for …

    Schreibe Deinen Kommentar

    Disclaimer